Physicians' Academy for Cardiovascular Education
Three speakers will provide guidance and insights on the treatment of patients with atrial fibrillation or venous thromboembolism in clinical practice. Watch the presentations and answer the questions!
If HFpEF patients also have atrial fibrillation and/or flutter, they are at increased risk of HF hospitalization or CV death, as shown by a post-hoc analysis of the PARAGON-HF trial.
Prof. Storey guides us through the ESC guidelines for the prevention of thromboembolic events in patients with atrial fibrillation.
ACC 2022 The factor XIa inhibitor asundexian lowers bleeding rate compared with apixaban in patients with AF in the phase 2 PACIFIC-AF trial.
Prof. Hohnloser talks about innovations in screening for AF. He also gives an overview of clinical outcomes with anticoagulation therapy in AF and discusses updates in recent AF guidelines.
The results of an observational study suggest that treatment with DOAC may be associated with a positive net clinical benefit compared with VKA and no anticoagulation treatment in patients with AF at low stroke risk.
Andexanet alfa specifically binds and sequesters factor Xa inhibitors. A study investigated the efficacy and safety of andexanet alfa in patients on edoxaban with acute major bleeding.
AHA 2021 In this video, prof. Marcus explains the methodology of n-of-1 trials in the I-STOP-AF trial and summarizes the findings.
AHA 2021 In the I-STOP AF trial, n-of-1 trials with individual triggers did not result in a change in AF-related quality of life compared to monitoring only.
AHA 2021 The Fitbit Heart study examined whether a novel photoplethysmography (PPG) software algorithm for Fitbit wearables can identify atrial fibrillation in a large population.
AHA 2021 A novel software algorithm with input of irregular heart rhythm detection by Fitbit wearables had a positive predictive value of 98% for undiagnosed atrial fibrillation (AF).
AHA 2021 The majority of cognitive outcome tests was not different between AF patients treated with dabigatran or warfarin after two years in the GIRAF trial.
